Resources
- sort by:
- Relevance
- Date
- Popularity
- International EECP Patient Registry Data Updated At the American College of Cardiology 2000
- Business/Health Editors WESTBURY, NY--BUSINESS WIRE--March 17, 2000 Quality of life and angina results persist or improve six months after completion of EECP therapy Vasomedical, Inc. (Nasdaq:VASO) announced today that updated clinical outcomes from the International EECP Patient Registry IEPR were presented at an IEPR participants' meeting...
- Research articles 2000-03-17
- U.S. Physical Therapy, Ballantyne of Omaha, Riverdeep Group, American Business Financial Services, and EDAP TMS S.A. Conference Calls to be Broadcast On Investor Broadcast Network Over the Internet
- Business Editors/Hi-Tech Writers PHILADELPHIA--BUSINESS WIRE--Nov. 7, 2000 U.S. Physical Therapy, Inc. (Nasdaq:USPH), Ballantyne of Omaha, Inc. (NYSE:BTN), Riverdeep Group plc (Nasdaq:RVDP), American Business Financial Services, Inc. (Nasdaq:ABFI) and EDAP TMS S.A. (Nasdaq:EDAPY)will broadcast their investor communication conference calls over the Internet, Investor Broadcast Network announced. U.S. Physical...
- Research articles 2000-11-07
- [0] U.S. Physical Therapy, Ballantyne of Omaha, Riverdeep Group, American Business Financial Services, and EDAP TMS S.A. Conference Calls to be Broadcast On Investor Broadcast Network Over the Internet
- Business Editors/Hi-Tech Writers PHILADELPHIA--BUSINESS WIRE--Nov. 7, 2000 U.S. Physical Therapy, Inc. (Nasdaq:USPH), Ballantyne of Omaha, Inc. (NYSE:BTN), Riverdeep Group plc (Nasdaq:RVDP), American Business Financial Services, Inc. (Nasdaq:ABFI) and EDAP TMS S.A. (Nasdaq:EDAPY) will broadcast their investor communication conference calls over the Internet, Investor Broadcast Network announced. U.S....
- Research articles 2000-11-07
- BIOTRONIK Announces First Investigational Implant of the Tachos DR ICD with Atrial Therapy
- Business Editors LAKE OSWEGO, Ore.--BUSINESS WIRE--Dec. 22, 2000 Biotronik, Inc. announced today the first investigational implant of the Tachos DR ICD with Atrial Therapy. This device represents a significant milestone in the treatment of arrhythmias in both the atrium and ventricle. The Tachos DR ICD with Atrial...
- Research articles 2000-12-22
- Multi-Link Telecommunications, Video Network Communications, U.S. Physical Therapy, Petco Animal Supplies and the Bon-Ton Stores Conference Calls to be Broadcast On Investor Broadcast Network Over the Internet
- Business Editors/Hi-Tech Writers PHILADELPHIA--BUSINESS WIRE--May 12, 2000 Multi-Link Telecommunications, Inc. (NASDAQ: MLNK), Video Network Communications, Inc. (NASDAQ: VNCI), U.S. Physical Therapy, Inc. (NASDAQ: USPH), Petco Animal Supplies, Inc. (NASDAQ: PETC), and The Bon-Ton Stores, Inc. (NASDAQ: BONT) will broadcast their investor communication conference calls over the Internet, Investor...
- Research articles 2000-05-12
- PhotoLoft.com, VitaminShoppe.com, Alysis Technologies, U.S. Physical Therapy, and Health Systems Design Conference Calls to be Broadcast On Investor Broadcast Network Over the Internet
- Business Editors/Hi-Tech Writers PHILADELPHIA--BUSINESS WIRE--Aug. 11, 2000 PhotoLoft.com Inc. (OTC BB: LOFT), VitaminShoppe.com, Inc. (Nasdaq: VSHP), Alysis Technologies, Inc. (Nasdaq: ALYS), U.S. Physical Therapy, Inc. (Nasdaq: USPH), and Health Systems Design Corporation (Nasdaq: HSDC) will broadcast their investor communication conference calls over the Internet, Investor Broadcast Network announced....
- Research articles 2000-08-11
- Vasomedical Expands EECP Education To Clinicians Specializing In Diabetes; EECP Therapy Is Being Presented For The First Time At Two International Scientific Sessions This Summer
- Business & Medical Editors WESTBURY, N.Y.--BUSINESS WIRE--June 12, 2000 Vasomedical, Inc. (Nasdaq: VASO) announced today that EECPR therapy is being presented to diabetes specialists at two international venues this Summer: the 60th Scientific Sessions of the American Diabetes Association ADA, scheduled for June 9-13 in San Antonio, and...
- Research articles 2000-06-12
- Decision Resources Study Forecasts Robust Growth In The Hormone Replacement Therapy Market
- The growing number of postmenopausal women has focused pharmaceutical development on the dynamic hormone replacement therapy HRT market, an area that will continue to thrive over the next ten years. Hormone Replacement Therapy, a new study from Decision Resources, Inc., identifies the market drivers that will create opportunities for novel...
- Research articles 1970-01-01
- Nexell Therapeutics Recognized for Contributions Made to Cell Therapy Industry
- Business Editors and Health/Medical Writers IRVINE, Calif.--BUSINESS WIRE--Jan. 12, 2000 Nexell Therapeutics Inc. (Nasdaq:NEXL) announced today that the company has been awarded Frost & Sullivan's 1999 Marketing Strategy Award, one of the Market Engineering Leadership Awards presented to companies that made a positive contribution to the growing U.S....
- Research articles 2000-01-12
- Health Care Financing Administration Issues National Coverage Policy for Visudyne(TM) Therapy.
- ATLANTA, GA, and VANCOUVER, BC, Nov 10, 2000 CIBA Vision Corporation, the eye care unit of Novartis AG (NYSE: NVS), and QLT Inc. (NASDAQ: QLTI; TSE: QLT) today announced that the Health Care Financing Administration HCFA has issued its national coverage policy for VisudyneTM...
- Research articles 2000-11-10
- Health Care Financing Administration Issues National Coverage Policy For Visudyne Therapy.
- ATLANTA and VANCOUVER, British Columbia, Nov 10, 2000 CIBA Vision Corporation, the eye care unit of Novartis AG (NYSE: NVS), and QLT Inc. (Nasdaq: QLTI; Toronto) today announced that the Health Care Financing Administration HCFA has issued its national coverage policy for VisudyneTM (verteporfin...
- Research articles 2000-11-10
- CPMP recommends approval in Europe for Visudyne therapy in the treatment of pathologic myopia.
- ATLANTA, GA and VANCOUVER, BC, Dec 15, 2000 CIBA Vision Corporation, the eye care unit of Novartis AG (NYSE: NVS), and QLT Inc.(NASDAQ: QLTI; TSE:QLT) announced today that the Committee for Proprietary Medicinal Products CPMP of the European Medicines Evaluation Agency EMEA has recommended...
- Research articles 2000-12-15
- HealthTronics, Inc. Enters Veterinary Market Through Agreement With Shock Waves, Inc
- Business Editors MARIETTA, Ga,--BUSINESS WIRE--March 23, 2000 HealthTronics, Inc. (NASDAQ:HTRN) has entered into an agreement with Shock Waves, Inc., to introduce the EquiTronTM into the United States. The EquiTron is a veterinary extracorporeal shock wave therapy system VESWT designed specifically for the treatment of animals....
- Research articles 2000-03-23
- Bioenvision Readies Lead Product for Market; Reports Substantive Progress On Four Platform Technologies During Year Ended June 30, 2000
- Business Editors/Health Writers NEW YORK--BUSINESS WIRE--Nov. 15, 2000 Bioenvision Inc, (OTCBB: BIOV), a development stage anti-cancer biopharmaceutical company, today reported a net loss of $1,495,509 for the fiscal year ended June 30, 2000. The Company also stated that it intends to market Modrefen, its lead product, in...
- Research articles 2000-11-15
- ZEVEX Subsidiary and Dynatronics to Offer Y2K Software Upgrade for the Dynatron 2000 System
- SALT LAKE CITY--BW HealthWire--Sept. 8, 1999-- ZEVEX International, Inc. (NASDAQ NM: ZVXI) and Dynatronics Corporation (NASDAQ SC: DYNT) today announced the signing of a joint agreement through which Dynatron 2000 physical evaluation system owners will be offered the fully Y2K-compliant Windows-based TrackerTM software and hardware manufactured by JTech Medical...
- Research articles 1999-09-08
- New Investigational Data Presented On Rituxan Plus Chemotherapy as Potential Front-line Therapy
- Business Editors and Health/Medical Writers SAN FRANCISCO--BUSINESS WIRE--Dec. 5, 2000 Low-Grade Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Studies Presented at ASH Meeting Genentech, Inc. (NYSE: DNA) and IDEC (Nasdaq: IDEC) today announced positive preliminary data from small Phase II investigational studies examining the role of RituxanR...
- Research articles 2000-12-05
- DUSA Pharmaceuticals Updates Investors at JP Morgan H&Q Healthcare Conference; Announces 100 BLU-U Contracts Signed During Q4 2000
- Business Editors, Health/Medical Writers WILMINGTON, Mass.--BW HealthWire--Jan. 10, 2001 DUSA Pharmaceuticals, Inc. (Nasdaq:DUSA) updated investors today at the JP Morgan H&Q Healthcare Conference in San Francisco. Dr. Geoffrey Shulman, DUSA's President and CEO, and Dr. Stuart Marcus, the Company's VP, Scientific Affairs and CSO, discussed progress in...
- Research articles 2001-01-10
- Sutter Health Purchases Mediware's WORx for Pharmacy Solution
- Business Editors & Health/Medical Writers LENEXA, Kan.--BW HealthWire--Oct. 30, 2000 Mediware Information Systems, Inc. (Nasdaq:MEDW), announced today that Sutter Health, one of Northern California's leading non-profit provider of health care services and programs, has purchased the WORxTM Drug Therapy Management System. WORx is Mediware's industry-leading drug therapy...
- Research articles 2000-10-30
- QLT announces Visudyne(TM) sales for third quarter Company confident of continued strong growth in sales.
- VANCOUVER, Oct 11, 2000 Following today's release of third quarter sales by Novartis AG (NYSE: NVS), QLT Inc. (NASDAQ: QLTI; TSE: QLT) reported global VisudyneTM therapy sales of U.S. $31 million (CDN $46.5 million or 53 million Swiss Francs) for the quarter ended September...
- Research articles 2000-10-11
- U.S. Bancorp Piper Jaffray Transfers Coverage of BMET with a Strong Buy Rating and $45 Price Target
- Business Editors MINNEAPOLIS--BUSINESS WIRE--March 2, 2000 U.S. Bancorp Piper Jaffray Senior Medical Technology Analyst Scott Davidson yesterday assumed coverage of Biomet, Inc. (BMET--$32, a) with a Strong Buy rating and a 12-month price target of $45, based on a multiple of 24 times his calendar 2001 earnings per...
- Research articles 2000-03-02
- << Previous
- page 1 of 2
- Next >>
Presented by American Express